New product aims to give CROs and sponsors a competitive advantage
goBalto, Inc., the leading provider of cloud-based clinical study startup solutions, announced today the release of Analyze, a reporting tool that provides a real-time view into clinical operations data.
With Analyze, study managers now gain deeper, instant insight into performance across accounts, portfolios, studies, countries, and sites. Users can also customize and share reports, internally and externally to members of partnering organizations. Customers can create new reports based on the standard ones available in Analyze, or build new, ad-hoc reports using an easy to use editing interface.
Analyze interacts seamlessly with goBalto’s flagship product, Activate, where information about sites, documents, submissions, milestones, and the status of activities related to them are tracked and managed. Analyze is also hosted in the cloud, so it can be accessed anytime and anywhere.
Analyze enables support for analytics by allowing you to instantly view status, quantify your team’s performance, and discover meaningful patterns in your clinical study startup data.
Recognizing that good data increasingly translates to a competitive advantage for its customers, goBalto built Analyze with the goals of simplicity, completeness, and flexibility. Customizable reports, drag and drop visualizations, and interactive dashboards allow decision makers to make faster, better decisions that improve performance and directly impact their clinical study startup conduct.
“Our customers were eager for a solution like Analyze,” said Andrea Sim, goBalto VP Product. “They’re already embracing all of the advantages that come with using Activate. Now, we’re providing them with the ability to gain even further insight into their study startup status, cycle times, and bottlenecks. Analyze is where big data meets and exceeds our customer’s needs.”
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.